PCSK9 Program: Initial Data for the Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102 Expected in the Second Quarter of 2025: VERVE-102, a novel, investigational base editing medicine targeting ...

and high intensity according to their ability to reduce low-density lipoprotein cholesterol (LDL-C). Thirdly, patients were divided into low- and high-NHR groups according to the median value of NHR.

Request permissions for this article. Department of Medicine, Leon H. Charney Division of Cardiology (S.Z., B.-X.L., A.C., M.F., E.A.F., S.P.H.), New York University ...